Thyrocare Tech is down 3% after reporting dismal first-quarter profits

Thyrocare Technologies shares decreased more than 3% in early trade on August 2, a day after the business disclosed weak earnings for the April-June quarter FY24, resulting in a drop in profit and profitability.

The diagnostics company's net profit for the first quarter fell 20.3% YoY to Rs 17.30 crore, down from Rs 22 crore in the previous year. Despite a 5.6% YoY increase in revenue to Rs 134.9 crore in April-June, the bottom line fell.

The company attributed the slow growth to the closure of a contract from Municipal Corporation of Greater Mumbai (MCGM) and a drop in its API (Active Pharmaceutical Ingredients) business.

Furthermore, the operating profit margin, or EBITDA margin, remained under pressure, falling to 25.4% in April-June from 28.2% in the previous fiscal quarter.

In the future, the company intends to expand internationally by bringing its business-to-business approach to new regions to provide diagnostics solutions.

On August 1, the company also announced that it has gained National Accreditation Board for Testing and Calibration Laboratories (NABL) certification for nine more processing laboratories in Bhopal, Guwahati, Bangalore, Chennai, Patna, Bhubaneswar, Raipur, Lucknow, and Ranchi.

Thyrocare currently has 18 NABL-accredited laboratories across India, accounting for 64% of its overall lab network, with the number projected to grow further.

Source: Media Reports

Top stories

Zee to Raise Funds Worth $239 mln via FCCBs

4 mins read . 19 Jul 2024 . 05:09 AM


Will Market Bloom in Green and Break Budget-Day Jinx on July 23?

4 mins read . 17 Jul 2024 . 12:19 PM


Interesting Facts to Know Ahead of Union Budget 2024

5 mins read . 17 Jul 2024 . 12:12 PM

Related Blogs

Share Market


15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 1 people read

Share Market


11 mins read . 08 Jul 2024

How to Withdraw SIP Amount?

  • 1 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions